STAAR Surgical's Q2 Surge
STAAR Surgical Reports 111% Q2 Revenue Growth, Returns to Profit After Prior-Year Loss.
Key Points
STAAR insiders have been net buyers, with PARTNERS, L.P. BROADWOOD making 6 purchases totaling about $12.27 million for 670,213 shares over the last six months.
In Q2 2026, revenue excluding China was $41.2 million, up 6% year over year, while EMEA revenue declined about 1% YoY.
STAAR indicated its Nidau facility is planned to supply all EVO lenses for China during 2026, signaling a major supply-chain alignment for China.
Analyst expectations were mixed: one report noted GAAP EPS of $0.16 was about 12.6% above consensus, while another noted pre-release estimates of around $0.21–$0.22.
STAAR Surgical posted a massive Q2 2026 quarter, with net sales of $93.5 million — up 111% year over year — and a swing to net income of $8.1 million after a loss in the same period last year, according to TipRanks. GAAP earnings came in at $0.16 per diluted share, which Yahoo Finance noted was 12.6% above analyst consensus.
Despite the strong numbers, the stock fell in after-hours trading, hovering around $25.41. The results reflected a company leaning hard into China, which alone contributed $52.3 million — more than half of total revenue — according to Quartr.
China Fuels a 111% Revenue Explosion
China was the clear engine behind STAAR's growth. The Asia-Pacific region surged 189% year over year, driven almost entirely by China's $52.3 million in sales, according to Quartr. That means China made up more than 55% of total company revenue in the quarter.
Outside China, the picture was more modest. Revenue excluding China was $41.2 million, up just 6% year over year, according to StockStory. EMEA sales actually slipped about 1% year over year. Americas grew 12%, but those gains were dwarfed by the China surge.
Margins Improve as Profits Return After Prior-Year Loss
STAAR posted a gross margin of 74.5% in Q2, a clear improvement from recent quarters, according to TipRanks. Operating income reached $10.1 million, and adjusted EBITDA hit $20.0 million. The company carries no debt and holds $181.5 million in cash and investments.
The net income of $8.1 million reversed a net loss from Q2 2025. Three strategic priorities drove the quarter: revenue growth, profit expansion, and faster product innovation. Management reaffirmed momentum despite ongoing geopolitical and operational pressures, according to Quartr.
EPS Beat Splits Analysts, Stock Falls Anyway
The earnings picture was mixed depending on which benchmark you used. Yahoo Finance reported the $0.16 GAAP EPS beat consensus by 12.6%. But some analysts had set pre-release estimates of $0.21 to $0.22 per share — making the result look like a miss against higher expectations.
That gap may explain why the stock dropped after hours even as headline numbers looked strong. StockStory reported the stock fell despite the 111% sales growth, a pattern common when investor expectations outrun reported results.
Insiders Buy Shares as Alcon Merger Falls Apart
Company insiders have been buying the stock in recent months. BROADWOOD PARTNERS, L.P. made 6 purchases totaling about $12.27 million — acquiring 670,213 shares over the last six months, according to TipRanks. That kind of insider buying often signals confidence in the company's direction.
The buying comes after STAAR terminated its proposed merger with Alcon following a shareholder vote. The company is now moving forward independently, with its Nidau facility set to supply all EVO lenses for China throughout 2026 — a key supply-chain move that locks in its China growth strategy, according to Quartr.
Sentiment
Mostly PositivePublishers
12
Articles
17
Reach
29
